文献速递湿疹皮炎与荨麻疹

特应性皮炎一线免疫抑制治疗的药物生存期与停药后生存期:甲氨蝶呤与环孢素比较

Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-03-06

本研究回顾性比较甲氨蝶呤与环孢素作为中重度特应性皮炎一线免疫抑制治疗的药物生存期和停药后生存期。56例患者中环孢素组25例、甲氨蝶呤组31例,甲氨蝶呤中位药物生存期23个月显著长于环孢素的8个月(P<0.0001),中位停药后生存期12个月也显著长于环孢素的2个月。

要点

  • 甲氨蝶呤中位药物生存期23个月,环孢素8个月,差异显著(P<0.0001)。
  • 基线后6个月,甲氨蝶呤组93%仍在治疗,环孢素组63%。
  • 甲氨蝶呤中位停药后生存期12个月,环孢素2个月,差异显著。

核心结论

  • 甲氨蝶呤用药持续时间长于环孢素,两者治疗特征不同;停药后生存期可作为评估停药后疗效维持的新工具。
  • 这是日常实践中甲氨蝶呤与环孢素作为中重度特应性皮炎一线免疫抑制治疗的首次直接比较。

研究设计与样本

  • 回顾性研究,纳入2007年至2016年间接受甲氨蝶呤或环孢素作为一线免疫抑制治疗的中重度特应性皮炎患者。
  • 共纳入56例患者,其中环孢素组25例,甲氨蝶呤组31例,中位年龄34±15岁。
  • 收集停药原因包括疾病控制、治疗失败、不良事件、妊娠和不依从。
  • 采用Kaplan-Meier法进行药物生存期和停药后生存期分析,采用单因素和多因素Cox回归分析预测因素。

主要发现

  • 停药原因为疾病控制与其他原因之间无显著差异(P=0.11)。
  • 甲氨蝶呤中位药物生存期23个月,显著长于环孢素的8个月(P<0.0001)。
  • 基线后6个月,甲氨蝶呤组93%患者仍在治疗,环孢素组为63%。
  • 甲氨蝶呤中位停药后生存期12个月,显著长于环孢素的2个月。
  • 仅环孢素治疗是药物生存期和停药后生存期缩短的预测因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cyclosporine and methotrexate are the two preferred first-line immunosuppressive treatments in atopic dermatitis. The aim of this study was to compare the treatment profiles of methotrexate and cyclosporine in daily practice as the first-line immunosuppressive treatment in atopic dermatitis, using two survival analyses, 'drug survival' (time on the drug) and 'postdrug survival' (time between two drugs). METHODS: Retrospective study including patients with moderate-to-severe atopic dermatitis treated with methotrexate or cyclosporine as the first-line immunosuppressive treatment. The reasons for discontinuation of treatment were collected as follows: controlled disease, treatment failure, side event pregnancy and non-compliance. 'Drug survival' and 'postdrug survival' analyses were performed using the Kaplan-Meier method and predictive factors were analysed using uni- and multivariate Cox regression analyses. RESULTS: Fifty-six patients, among whom 25 patients treated with cyclosporine and 31 with methotrexate (median age: 34 ± 15 years), were included between 2007 and 2016. Reasons for discontinuation were not significantly different between 'controlled disease' and other reasons (P = 0.11). The median 'drug survival' was significantly longer for methotrexate (23 months) than for cyclosporine (8 months) (P < 0.0001). Six months from baseline, 93% of patients treated with methotrexate were still being treated vs 63% among patients treated with cyclosporine. The median of 'postdrug survival' was significantly longer for methotrexate (12 months) than for cyclosporine (2 months). Only treatment with CYC was a predictive factor for decreased 'drug survival' and 'postdrug survival'. CONCLUSION: This is the first direct comparison between methotrexate and cyclosporine as first-line immunosuppressive treatments for moderate-to-severe atopic dermatitis in daily practice. We evidenced two different treatment profiles: the duration of methotrexate administration is longer than that of cyclosporine. 'Postdrug survival' could be a new tool to assess the maintenance of effect of a drug after withdrawal in atopic dermatitis, and more broadly in chronic skin disease.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Law Ping Man S, Bouzillé G, Beneton N, et al. Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine. J Eur Acad Dermatol Venereol. 2018. PMID: 29444359. doi:10.1111/jdv.14880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。